James J. Harding, MD, on New Data on Neratinib for HER2-Positive Biliary Tract Cancer

Posted: Thursday, October 6, 2022

James J. Harding, MD, of Memorial Sloan Kettering Cancer Center, discusses findings from the SUMMIT trial of neratinib for patients with HER2-positive biliary tract cancer, its modest activity, and other agents being considered for investigational regimens that might improve responses.